DBV Technologies | DBVT - Assets


DBV Technologies reported $215.4M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amarin USD 634.08M 9.72M Sep/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
DBV Technologies USD 215.4M 7.8M Sep/2026
Galectin Therapeutics USD 27.65M 1.76M Jun/2024
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
Insmed USD 2.23B 123.49M Sep/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
United Therapeutics USD 7.22B 505.9M Jun/2026